• Profile

Combination of &aplha;-blocker and 5&aplha;-reductase inhibitor for treatment of benign prostatic hyperplasia

Clinical and Investigative Medicine Oct 30, 2017

Kang D, et al. - A comparative scrutiny was performed of an α-blocker monotherapy alone with a combination of α-blocker plus 5α-reductase in treatment of benign prostatic hyperplasia (BPH). The yielded data pointed towards the combined &aplha;-blocker plus 5&aplha;-reductase therapy being more beneficial in treating benign prostatic hyperplasia than the &aplha;-blocker monotherapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen